{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:57:38Z","timestamp":1789822658616,"version":"4.0.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"26","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.vaccine.2024.126394","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T21:48:44Z","timestamp":1728078524000},"page":"126394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["SpiN-Tec: A T cell-based recombinant vaccine that is safe, immunogenic, and shows high efficacy in experimental models challenged with SARS-CoV-2 variants of concern"],"prefix":"10.1016","volume":"42","author":[{"given":"Nat\u00e1lia S.","family":"Hojo-Souza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falia T.","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziella G.","family":"Rivelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick O.","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano R.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00eddia P.","family":"Faustino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nat\u00e1lia","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fl\u00e1via F.","family":"Bagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex F.","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna","family":"Rattis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine L.","family":"Louren\u00e7o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabela P.","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna R.D.","family":"Assis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariela","family":"Piccin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fl\u00e1vio G.","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edison","family":"Durigon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o S.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renan P.","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisele A.C.","family":"Goulart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helton","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula S.","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santuza R.","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo T.","family":"Gazzinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.126394_bb0005","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ijid.2022.06.046","article-title":"Nucleocapsid as a next-generation COVID-19 vaccine candidate","volume":"122","author":"Oronsky","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126394_bb0010","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.1038\/s41467-022-32547-y","article-title":"Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein","volume":"13","author":"Castro","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2024.126394_bb0015","doi-asserted-by":"crossref","DOI":"10.1126\/science.abm0829","article-title":"mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern","volume":"374","author":"Goel","year":"2021","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.vaccine.2024.126394_bb0020","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cell.2022.01.015","article-title":"SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from alpha to omicron","volume":"185","author":"Tarke","year":"2022","journal-title":"Cell"},{"issue":"7901","key":"10.1016\/j.vaccine.2024.126394_bb0025","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41586-022-04460-3","article-title":"T cell responses to SARS-CoV-2 spike cross-recognize Omicron","volume":"603","author":"Keeton","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2024.126394_bb0030","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abo2202","article-title":"Divergent SARS-CoV-2 omicron\u2013reactive T and B cell responses in COVID-19 vaccine recipients","volume":"7","author":"GeurtsvanKessel","year":"2022","journal-title":"Sci immunol"},{"key":"10.1016\/j.vaccine.2024.126394_bb0035","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/s41591-022-01700-x","article-title":"Ancestral SARS-CoV-2-specific T cells cross-recognize the omicron variant","volume":"28","author":"Gao","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2024.126394_bb0040","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abj1750","article-title":"SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccines","volume":"6","author":"Geers","year":"2021","journal-title":"Sci Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2024.126394_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109664","article-title":"Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2","volume":"36","author":"Dangi","year":"2021","journal-title":"Cell Rep"},{"issue":"22","key":"10.1016\/j.vaccine.2024.126394_bb0050","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg7156","article-title":"Immunization with RBD-P2 and N protects against SARS-CoV-2 in nonhuman primates","volume":"7","author":"Hong","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.vaccine.2024.126394_bb0055","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(22)00094-0","article-title":"Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study","volume":"399","author":"Clemens","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.126394_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-022-30340-5","article-title":"Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 omicron variant","volume":"13","author":"Zuo","year":"2022","journal-title":"Nat Commun"},{"issue":"18","key":"10.1016\/j.vaccine.2024.126394_bb0065","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2217\/nnm-2023-0122","article-title":"Quality attributes of CTVad1, a nanoemulsified adjuvant for phase I clinical trial of SpiN COVID-19 vaccine","volume":"18","author":"Dias Assis","year":"2023","journal-title":"Nanomedicine"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2024.126394_bb0070","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-1759(98)00170-7","article-title":"A statistically defined endpoint titer determination method for immunoassays","volume":"221","author":"Frey","year":"1998","journal-title":"J Immunol Methods"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126394_bb0075","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41541-023-00616-y","article-title":"Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern","volume":"8","author":"Azevedo","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2024.126394_bb0080","series-title":"The laboratory rat","author":"Sharp","year":"2012"},{"key":"10.1016\/j.vaccine.2024.126394_bb0085","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/ame2.12041","article-title":"Reference values for selected hematological, biochemical and physiological parameters of Sprague-Dawley rats at the animal house, Faculty of Medicine, University of Colombo","volume":"1","author":"Delwatta","year":"2018","journal-title":"Sri Lanka Anim Model Exp Med"},{"key":"10.1016\/j.vaccine.2024.126394_bb0090","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1292\/jvms.10-0489","article-title":"Comparison of the blood coagulation profiles of ferrets and rats","volume":"73","author":"Takahashi","year":"2011","journal-title":"J Vet Med Sci"},{"issue":"9","key":"10.1016\/j.vaccine.2024.126394_bb0095","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1093\/cid\/ciaa325","article-title":"Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a Golden Syrian Hamster model: implications for disease pathogenesis and transmissibility","volume":"71","author":"Chan","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"7818","key":"10.1016\/j.vaccine.2024.126394_bb0100","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41586-020-2342-5","article-title":"Pathogenesis and transmission of SARS-CoV-2 in golden hamsters","volume":"583","author":"Sia","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2024.126394_bb0105","author":"WHO"},{"key":"10.1016\/j.vaccine.2024.126394_bb0110","article-title":"Vaccines for COVID-19: a systematic review of immunogenicity, current development, and future prospects","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2024.126394_bb0115","first-page":"162","article-title":"COVID-19 genomics UK consortium, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness","volume":"21","author":"Carabelli","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2024.126394_bb0120","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.cell.2022.01.029","article-title":"T cell reactivity to the SARS-CoV-2 omicron variant is preserved in most but not all individuals","volume":"185","author":"Naranbhai","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2024.126394_bb0125","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-022-04465-y","article-title":"Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 omicron","volume":"603","author":"Liu","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2024.126394_bb0130","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2024.126394_bb0135","article-title":"Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases","volume":"2","author":"Tarke","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2024.126394_bb0140","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41590-020-00808-x","article-title":"SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition","volume":"22","author":"Nelde","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2024.126394_bb0145","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abp9770","article-title":"Cell surface SARS-CoV-2 nucleocapsid protein modulates innate and adaptive immunity","volume":"8","author":"L\u00f3pez-Mu\u00f1oz","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.vaccine.2024.126394_bb0150","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1128\/JVI.01279-20","article-title":"The SARS-CoV-2 N protein is a good component in a vaccine","volume":"94","author":"Ahl\u00e9n","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.126394_bb0155","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.24479","article-title":"Nucleocapsid protein of SARS-CoV-2 is a potential target for developing new generation of vaccine","volume":"36","author":"Feng","year":"2022","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.vaccine.2024.126394_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12985-023-01968-6","article-title":"The SARS-CoV-2 nucleocapsid protein: its role in the viral life cycle, structure and functions, and use as a potential target in the development of vaccines and diagnostics","volume":"20","author":"Wu","year":"2023","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2024.126394_bb0165","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41590-020-0782-6","article-title":"Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19","volume":"21","author":"Peng","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2024.126394_bb0170","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2022.2164219","article-title":"The role of SARS-CoV-2 nucleocapsid protein in antiviral immunity and vaccine development","volume":"12","author":"Yu","year":"2023","journal-title":"Emerg Microbes & infect"},{"key":"10.1016\/j.vaccine.2024.126394_bb0175","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41586-023-06487-6","article-title":"Neutralization, effector function and immune imprinting of omicron variants","volume":"621","author":"Addetia","year":"2023","journal-title":"Nat"},{"key":"10.1016\/j.vaccine.2024.126394_bb0180","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq1945","article-title":"Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 omicron and Delta variants in preclinical models","volume":"14","author":"Hajnik","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2024.126394_bb0185","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/erv.12.140","article-title":"The history of MF59\u00ae adjuvant: a phoenix that arose from the ashes","volume":"12","author":"O\u2019Hagan","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2024.126394_bb0190","doi-asserted-by":"crossref","DOI":"10.1038\/srep19570","article-title":"Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens","volume":"6","author":"Knudsen","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2024.126394_bb0195","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41577-022-00813-1","article-title":"Beyond neutralization: fc-dependent antibody effector functions in SARS-CoV-2 infection","volume":"23","author":"Zhang","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2024.126394_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110368","article-title":"A fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection","volume":"38","author":"Beaudoin-Bussi\u00e8res","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2024.126394_bb0205","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41392-021-00759-1","article-title":"Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients","volume":"6","author":"Yu","year":"2021","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.vaccine.2024.126394_bb0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247640","article-title":"Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma","volume":"16","author":"Tso","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.126394_bb0215","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/eji.202149470","article-title":"Natural killer cell-mediated ADCC in SARS-CoV-2-infected individuals and vaccine recipients","volume":"52","author":"Hagemann","year":"2022","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2024.126394_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111544","article-title":"BNT162b2-induced neutralizing and non-neutralizing antibody functions against SARS-CoV-2 diminish with age","volume":"41","author":"Bates","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2024.126394_bb0225","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.chom.2022.03.029","article-title":"SARS-CoV-2 omicron triggers cross-reactive neutralization and fc effector functions in previously vaccinated, but not unvaccinated, individuals","volume":"30","author":"Richardson","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2024.126394_bb0230","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/ID9.0000000000000053","article-title":"Potential of antibody-dependent cellular cytotoxicity in acute and recovery phases of SARS-CoV-2 infection","volume":"2","author":"Cui","year":"2022","journal-title":"Infect Dis Immun"},{"issue":"10295","key":"10.1016\/j.vaccine.2024.126394_bb0235","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(21)01420-3","article-title":"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"398","author":"Borobia","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.vaccine.2024.126394_bb0240","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/s41591-021-01464-w","article-title":"Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19\/mRNA vaccination","volume":"27","author":"Schmidt","year":"2021","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.vaccine.2024.126394_bb0245","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S2213-2600(21)00357-X","article-title":"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study","volume":"9","author":"Hillus","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126394_bb0250","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/s41467-022-29301-9","article-title":"Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2","volume":"13","author":"Hermosilla","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126394_bb0255","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1038\/s41467-022-32321-0","article-title":"Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens","volume":"13","author":"Klemis","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2024.126394_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104294","article-title":"Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2","volume":"85","author":"Vogel","year":"2022","journal-title":"EBioMedicine"},{"issue":"10","key":"10.1016\/j.vaccine.2024.126394_bb0265","doi-asserted-by":"crossref","first-page":"1390.e1","DOI":"10.1016\/j.cmi.2022.04.019","article-title":"Heterologous ChAdOx1 and Bnt162b2 vaccination induces strong neutralizing antibody responses against SARS-CoV-2 including delta variant with tolerable reactogenicity","volume":"28","author":"Bae","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2024.126394_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103761","article-title":"Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants","volume":"75","author":"Gro\u00df","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2024.126394_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109342","article-title":"Pre-existing humoral immunity and CD4+ T cell response correlate with cross-reactivity against SARS-CoV-2 omicron subvariants after heterologous prime-boost vaccination","volume":"251","author":"Shen","year":"2023","journal-title":"Clin Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2024.126394_bb0280","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.jiph.2023.07.017","article-title":"Heterologous vaccination (ChAdOx1 and BNT162b2) induces a better immune response against the omicron variant than homologous vaccination","volume":"16","author":"Yoo","year":"2023","journal-title":"J Infect Public Health"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24010764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24010764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T17:42:43Z","timestamp":1741887763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24010764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":56,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0264410X24010764"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126394","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SpiN-Tec: A T cell-based recombinant vaccine that is safe, immunogenic, and shows high efficacy in experimental models challenged with SARS-CoV-2 variants of concern","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126394","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126394"}}